MEDNAX (MD) Misses Q2 EPS by 19c, Miss on Revenues; Q3 EPS Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Mednax (MD) PT Lowered to $48 at Mizuho Securities
August 1, 2017 5:39 AM EDTMizuho Securities lowered its price target on Mednax (NYSE: MD) to $48.00 (from $62.00) while maintaining a Neutral rating.
Analyst Ann Hynes believes the company decision to step away from anesthesiology acquisitions in the NT will like mean headwinds are like to remain in the... More
Mednax (MD) PT Lowered to $46 at Jefferies; Reiterates Hold
July 31, 2017 8:19 AM EDTJefferies lowered its price target on Mednax (NYSE: MD) to $46.00 (from $53.00) while maintaining a Hold rating Following the company's 2Q.
On its Q2 earnings call, MD noted that given operating challenges in the anesthesia sector and acquisition valuations,... More
